Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

The Lancet. Respiratory medicine（2023）

引用 3|浏览68

暂无评分

摘要

For the Chinese translation of the abstract see Supplementary Materials section.

查看译文

关键词

lung cancer,befotertinib,icotinib,first-line,egfr-mutated,non-small-cell,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要